A new study in the New England Journal of Medicine shows that popular type 2 diabetes drug Avandia (generic name: rosiglitazone) raises a user’s heart attack risk by 43 percent. The Food and Drug Administration has issued a safety alert for the drug and say that more studies are needed to fully determine the drug’s risks.
